ArticleAntimicrobial agents and chemotherapy2024
Impact of porin deficiency on the synergistic potential of colistin in combination with β-lactam/β-lactamase inhibitors against ESBL- and carbapenemase-producing
Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- ESBL and carbapenemase-producing enteric pathogens in animal-origin foods: a one health perspective.Folia microbiologica · 2026Review
- Cumulative cefepime exposure in cancer patients is associated with an increased risk of ertapenem non-susceptible, meropenem susceptible Enterobacterales bacteremia.Microbiology spectrum · 2026Article
- Molecular Insights into Carbapenem Resistance inInternational journal of molecular sciences · 2026Review
- Chromosomal resistance mutations facilitate acquisition of multidrug-resistant plasmids inMicrobiology (Reading, England) · 2025Article
- Epidemiological and biological characteristics of IncR plasmids as multihost antibiotic resistance carriers.Frontiers in microbiology · 2025Review
- Antimicrobial resistance at a turning point: microbial drivers, one health, and global futures.Frontiers in microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combinations of colistin and β-lactam/β-lactamase inhibitors (BLBLIs) have shown
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.